Esperion
The Lipid Management Company

Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ESPR	
Last Trade:	44.74
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.24 (-0.534%)
Day Range	43.79 - 45.89
52-Week Range	9.40 - 57.38
Volume	859,945

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

Stock Performance



Press Releases [View all]

Aug 11, 2017
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 9, 2017
Esperion Prices Public Offering of Common Stock

Aug 8, 2017
Esperion Announces Proposed Public Offering of Common Stock

Aug 8, 2017
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results

Aug 8, 2017
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin

Financials [View all]

Second Quarter Financial Results

Feb 22, 2017
Annual Report (10-K)

Mar 6, 2017
Proxy Statement (DEF 14A)

Aug 8, 2017
Quarterly Report (10-Q)

May 4, 2017
Quarterly Report (10-Q)

Nov 3, 2016
Quarterly Report (10-Q)